Response rates were 75% first-line and 67% second-line; 79 patients had received the combination by May 15, and global Phase ...
Interesting Engineering on MSN
Watch: Four-legged robot solves giant Rubik’s cube without using hands
ETH Zurich’s Robotic Systems Lab has showcased its ANYmal-D solving a giant Rubik’s Cube ...
At median 15-month follow-up, 16 of 18 patients remained recurrence-free. A rectal cohort is enrolling to assess whether ...
Novartis reported 2Q26 revenue of $14.4 billion, as strong demand for newer medicines was largely offset by generic ...
Javier Ares analyses the 2027 Tour de France route, its mountain stages and time trials, and the chances of Pogacar, ...
The Met Police is trialling reduced enforcement of minor tag and curfew breaches, prioritising high-risk offenders amid pressure on police resources.
Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny—and what nuances do you need to know? Let’s dig in.
The Foundation of Stamina Built by the Gainsborough LineThe Tenno Sho (Autumn) was once a grueling long-distance race like ...
In an exclusive interview, the studio's CEO talks about surveying a real 800XP in Alabama, rebuilding it for MSFS 2024, plans for Marketplace free trials, and what keeps a small team going.
A Brazilian team has published a protocol for an assessor-blinded randomised pilot and feasibility trial comparing a ...
Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy.
The Crowbar nightclub of Tampa, Florida, never looked like much outside: a squat building with painted-over windows in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results